Forbion European Acquisition Corp.

Forbion European Acquisition Corp. (Nasdaq: FRBN) is a blank-check company sponsored by Forbion Capital Partners, a Dutch venture capital firm specializing in life sciences investment across Europe. The SPAC completed its initial public offering in 2021 and targets acquisition opportunities in the European life sciences and healthcare sector, reflecting Forbion's established deal-flow and domain expertise in that space. On October 24, 2023, the company filed an 8-K with the SEC under accession number 0001193125-23-261761, marking a notable corporate development in its lifecycle. FRBN represents one of the few SPACs with a distinctly European life sciences mandate to list on a U.S. exchange during the 2021 wave. Sign up for SpacDesk to access full filing history, timeline data, and deal analytics on FRBN and hundreds of other active and completed SPACs.